How to buy Seagen stock (SGEN)

Seagen is a biotechnology business based in the US. Seagen shares (SGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Seagen employs 3,256 staff and has a trailing 12-month revenue of around $2.3 billion.

Our top picks for where to buy Seagen stock

Buy Seagen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Seagen stock price (NASDAQ: SGEN)

Use our graph to track the performance of SGEN stocks over time.

Seagen shares at a glance

• Key figures

Information last updated 2024-03-03.

52-week range	$0.00 - $0.00
50-day moving average more info button	$217.43
200-day moving average more info button	$204.65
Wall St. target price	$229.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.00

Is it a good time to buy Seagen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Seagen stock undervalued or overvalued?

Valuing Seagen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Seagen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Seagen's PEG ratio

Seagen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 18.5286. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Seagen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Seagen financials

Revenue TTM	$2.3 billion
Gross profit TTM	$208 million
Return on assets TTM	-12.94%
Return on equity TTM	-27.93%
Profit margin	-32.61%
Book value	$13.52
Market Capitalization more info button	$43.2 billion

TTM: trailing 12 months

Seagen share dividends

We're not expecting Seagen to pay a dividend over the next 12 months.

Seagen share price volatility

Over the last 12 months, Seagen's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seagen's is 0.321. This would suggest that Seagen's shares are less volatile than average (for this exchange).

Seagen overview

Seagen Inc. , a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc. ; Genmab A/S; Merck; and RemeGen, Co. Ltd.

Frequently asked questions

What percentage of Seagen is owned by insiders or institutions?
Currently 0.814% of Seagen shares are held by insiders and 88.829% by institutions. How many people work for Seagen?
Latest data suggests 3,256 work at Seagen. When does the fiscal year end for Seagen?
Seagen's fiscal year ends in December. Where is Seagen based?
Seagen's address is: 21823 30th Drive SE, Bothell, WA, United States, 98021 What is Seagen's ISIN number?
Seagen's international securities identification number is: US81181C1045 What is Seagen's CUSIP number?
Seagen's Committee on Uniform Securities Identification Procedures number is: 812578102